214 related articles for article (PubMed ID: 36599553)
21. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial.
Peikert A; Bart BA; Vaduganathan M; Claggett BL; Kulac IJ; Kosiborod MN; Desai AS; Jhund PS; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Petersson M; Langkilde AM; McMurray JJV; Solomon SD; Vardeny O
JACC Heart Fail; 2024 Apr; 12(4):631-644. PubMed ID: 37767674
[TBL] [Abstract][Full Text] [Related]
22. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan.
Selvaraj S; Claggett BL; Böhm M; Anker SD; Vaduganathan M; Zannad F; Pieske B; Lam CSP; Anand IS; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2020 Apr; 75(14):1644-1656. PubMed ID: 32192799
[TBL] [Abstract][Full Text] [Related]
23. Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
Ostrominski JW; Thierer J; Claggett BL; Miao ZM; Desai AS; Jhund PS; Kosiborod MN; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Petersson M; Langkilde AM; McMurray JJV; Solomon SD; Vaduganathan M
JACC Heart Fail; 2023 Nov; 11(11):1491-1503. PubMed ID: 37226448
[TBL] [Abstract][Full Text] [Related]
24. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum.
Butt JH; Docherty KF; Claggett BL; Desai AS; Fang JC; Petersson M; Langkilde AM; de Boer RA; Cabrera Honorio JW; Hernandez AF; Inzucchi SE; Kosiborod MN; Køber L; Lam CSP; Martinez FA; Ponikowski P; Sabatine MS; Vardeny O; O'Meara E; Saraiva JFK; Shah SJ; Vaduganathan M; Jhund PS; Solomon SD; McMurray JJV
JACC Heart Fail; 2023 Apr; 11(4):375-388. PubMed ID: 36881399
[TBL] [Abstract][Full Text] [Related]
25. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.
Solomon SD; Vaduganathan M; Claggett BL; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Belohlavek J; Chiang CE; Willem Borleffs CJ; Comin-Colet J; Dobreanu D; Drozdz J; Fang JC; Alcocer Gamba MA; Al Habeeb W; Han Y; Cabrera Honorio JW; Janssens SP; Katova T; Kitakaze M; Merkely B; O'Meara E; Kerr Saraiva JF; Tereschenko SN; Thierer J; Vardeny O; Verma S; Vinh PN; Wilderäng U; Zaozerska N; Lindholm D; Petersson M; McMurray JJV
JACC Heart Fail; 2022 Mar; 10(3):184-197. PubMed ID: 35241246
[TBL] [Abstract][Full Text] [Related]
26. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Claggett B; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Jhund PS; Belohlavek J; Chiang CE; Borleffs CJW; Comin-Colet J; Dobreanu D; Drozdz J; Fang JC; Alcocer-Gamba MA; Al Habeeb W; Han Y; Cabrera Honorio JW; Janssens SP; Katova T; Kitakaze M; Merkely B; O'Meara E; Saraiva JFK; Tereshchenko SN; Thierer J; Vaduganathan M; Vardeny O; Verma S; Pham VN; Wilderäng U; Zaozerska N; Bachus E; Lindholm D; Petersson M; Langkilde AM;
N Engl J Med; 2022 Sep; 387(12):1089-1098. PubMed ID: 36027570
[TBL] [Abstract][Full Text] [Related]
27. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
McMurray JJV; Docherty KF; de Boer RA; Hammarstedt A; Kitzman DW; Kosiborod MN; Maria Langkilde A; Reicher B; Senni M; Shah SJ; Wilderäng U; Verma S; Solomon SD
Circulation; 2024 Mar; 149(11):825-838. PubMed ID: 38059368
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.
Kondo T; Butt JH; Curtain JP; Jhund PS; Docherty KF; Claggett BL; Vaduganathan M; Bachus E; Hernandez AF; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Kosiborod MN; Desai AS; Køber L; Ponikowski P; Sabatine MS; Solomon SD; McMurray JJV
Circ Heart Fail; 2023 Dec; 16(12):e010898. PubMed ID: 37886880
[TBL] [Abstract][Full Text] [Related]
30. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial.
Chatur S; Vaduganathan M; Claggett BL; Cunningham JW; Docherty KF; Desai AS; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez FA; Shah SJ; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Circulation; 2023 Nov; 148(22):1735-1745. PubMed ID: 37632455
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.
Martinez FA; Serenelli M; Nicolau JC; Petrie MC; Chiang CE; Tereshchenko S; Solomon SD; Inzucchi SE; Køber L; Kosiborod MN; Ponikowski P; Sabatine MS; DeMets DL; Dutkiewicz-Piasecka M; Bengtsson O; Sjöstrand M; Langkilde AM; Jhund PS; McMurray JJV
Circulation; 2020 Jan; 141(2):100-111. PubMed ID: 31736328
[TBL] [Abstract][Full Text] [Related]
32. Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER.
Peikert A; Vaduganathan M; Claggett BL; Kulac IJ; Foà A; Desai AS; Jhund PS; Carberry J; Lam CSP; Kosiborod MN; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Køber L; Ponikowski P; Sabatine MS; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Eur J Heart Fail; 2024 Apr; 26(4):912-924. PubMed ID: 38487939
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
Furtado RHM; Raz I; Goodrich EL; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Aylward P; Dalby AJ; Dellborg M; Dimulescu D; Nicolau JC; Oude Ophuis AJM; Cahn A; Mosenzon O; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
Circulation; 2022 May; 145(21):1581-1591. PubMed ID: 35510542
[TBL] [Abstract][Full Text] [Related]
34. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
[TBL] [Abstract][Full Text] [Related]
35. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction.
Butt JH; Kondo T; Jhund PS; Comin-Colet J; de Boer RA; Desai AS; Hernandez AF; Inzucchi SE; Janssens SP; Kosiborod MN; Lam CSP; Langkilde AM; Lindholm D; Martinez F; Petersson M; Shah SJ; Thierer J; Vaduganathan M; Verma S; Wilderäng U; Claggett BC; Solomon SD; McMurray JJV
J Am Coll Cardiol; 2022 Nov; 80(18):1705-1717. PubMed ID: 36041668
[TBL] [Abstract][Full Text] [Related]
36. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER.
Desai AS; Jhund PS; Claggett BL; Vaduganathan M; Miao ZM; Kondo T; Barkoudah E; Brahimi A; Connolly E; Finn P; Lang NN; Mc Causland FR; McGrath M; Petrie MC; McMurray JJV; Solomon SD
JAMA Cardiol; 2022 Dec; 7(12):1227-1234. PubMed ID: 36189985
[TBL] [Abstract][Full Text] [Related]
37. Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER.
Butt JH; Lu H; Kondo T; Bachus E; de Boer RA; Inzucchi SE; Jhund PS; Kosiborod MN; Lam CSP; Martinez FA; Vaduganathan M; Solomon SD; McMurray JJV
Eur J Heart Fail; 2023 Nov; 25(11):2078-2090. PubMed ID: 37634087
[TBL] [Abstract][Full Text] [Related]
38. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
Docherty KF; Anand IS; Chiang CE; Chopra VK; Desai AS; Kitakaze M; Verma S; Vinh PN; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Langkilde AM; Jhund PS; McMurray JJV
JACC Asia; 2022 Apr; 2(2):139-153. PubMed ID: 36339117
[TBL] [Abstract][Full Text] [Related]
39. Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial.
Chatur S; Cunningham JW; Vaduganathan M; Mc Causland FR; Claggett BL; Desai AS; Miao ZM; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez FA; Shah SJ; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Eur J Heart Fail; 2023 Jul; 25(7):1170-1175. PubMed ID: 37212168
[TBL] [Abstract][Full Text] [Related]
40. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function.
Chatur S; Vaduganathan M; Claggett BL; Mc Causland FR; Desai AS; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez FA; Shah SJ; Sabatine MS; Kober L; Ponikowski P; Merkely B; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2023 Nov; 82(19):1854-1863. PubMed ID: 37634707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
